News Releases Year: All News2020201920182017201620152014201320122011 Items per page All News2550 October 22, 2018 Summary ToggleAllena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-346 Read more October 18, 2018 Summary ToggleAllena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the Kidney with Presentations at Upcoming Medical Meetings Read more September 25, 2018 Summary ToggleAllena Pharmaceuticals to Present at Upcoming Investor Conferences in October Read more August 7, 2018 Summary ToggleAllena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference Read more August 7, 2018 Summary ToggleAllena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update Read more July 23, 2018 Summary ToggleAllena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease Read more June 19, 2018 Summary ToggleAllena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease Read more June 11, 2018 Summary ToggleAllena Pharmaceuticals Appoints Andrew A. F. Hack, M.D., Ph.D., to its Board of Directors Read more May 30, 2018 Summary ToggleAllena Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference Read more May 8, 2018 Summary ToggleAllena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update Read more Pagination First page First Previous page Previous … Page 3 Current page 4 Page 5 Page 6 … Next page Next Last page Last
